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Background: Aortic aneurysm is an increasingly common vascular disorder with fatal implication. However, there is
no established diagnosis other than that based on aneurysmal size. For this purpose, serum protein biomarkers for
aortic aneurysms are valuable. Although most of the studies on serum biomarker discovery have been based on
comparison of serum proteins from the patient group with those from the healthy group, we considered that
comparison of serial protein profiles such as those in presurgical and postsurgical sera within one patient would
facilitate identification of biomarkers since the variability of serial protein profiles within one patient is smaller than
that between groups. In this study, we examined serum proteins with differential levels in postsurgery compared
with those in presurgery after the removal of aneurysmal tissues in abdominal aortic aneurysm (AAA) and thoracic
aortic aneurysm (TAA) patients in order to identify potential serum biomarkers for AAAs and TAAs.
Results: A proteomic approach with an isobaric tag for relative and absolute quantitation (iTRAQ) labeling followed
by nano liquid chromatography (nanoLC)-matrix-assisted laser desorption ionization (MALDI)-time of flight (TOF/
TOF)-tandem mass spectrometry (MS/MS) was used. In the sera of patients with AAAs and TAAs, a total of 63 and
71 proteins with differential levels were further narrowed down to 6 and 8 increased proteins (≧1.3 fold,
postsurgical vs. presurgical) (p < 0.05, patient vs. control) and 12 and 17 decreased proteins (< 0.77 fold, postsurgical
vs. presurgical) (p < 0.05, patient vs. control) in postsurgical sera compared with those in presurgical sera,
respectively. All of the increased proteins in postsurgical sera of both AAA and TAA patients included several
known acute-phase proteins. On the other hand, in the decreased proteins, we found intriguing molecules such as
α-2-macroglobulin, gelsolin, kallistatin, and so on. Among them, we confirmed that kallistatin in both AAA and TAA
patients and α-2-macroglobulin in TAA patients showed decrease levels in postsurgical sera similar to those in
control sera by Western blot analysis with other sera from AAA and TAA patients.
Conclusions: Taken together, our findings suggest that Kallistatin and α-2-macroglobulin are potential serum
biomarkers for both AAA and TAA and TAA, respectively.
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Aortic aneurysm is a severe cardiovascular disease with
high mortality and morbidity. It is a complex disease
with genetic and environmental risk factors. Aneurysms
are described as abdominal aortic aneurysms (AAAs)
and thoracic aortic aneurysms (TAAs) in terms of their* Correspondence: matumoto@med.shimane-u.ac.jp
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reproduction in any medium, provided the oranatomic location. It is well known that both AAAs and
TAAs are associated with male gender, advanced age,
cigarette smoking, hypertension, and chronic obstructive
pulmonary disease. Both thoracic and abdominal aortas
are large vascular conduits with similarities in their cel-
lular components. However, thoracic and abdominal aor-
tas are distinct in their biochemical and biomechanical
properties, proteolytic profiles, inflammatory response,
and genetic factors [1]. These differences are implicated
in the distinct onset and expansion of aortic aneurysms
in the thoracic and abdominal regions. A significanttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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most common location for aneurysms is in the infrarenal
abdominal aorta, followed by the ascending thoracic aorta.
In addition, it has been shown that intimal atherosclerosis,
chronic transmural inflammation and elastic media de-
struction are associated with AAA growth, but many of
TAAs arise in the absence of atherosclerotic plaque de-
position. Preferably, TAAs are associated with the medial
degeneration that is commonly related to the loss of
vascular smooth muscle cells and destruction of medial
elastic fibers [2].
Most patients with aortic aneurysms are asymptomatic
until rupture of the aneurysm, which is often fatal. This
disease is diagnosed when the diameter reaches 30 mm
or more. However, there is no established medical thera-
peutics for small aneurysms. For this purpose, plasma/
serum protein biomarkers are available. Plasma or serum
is considered a suitable body fluid for biomarker discov-
ery since it is readily obtained via the least invasive
mode without the risk of surgery. Studies are needed to
find the serum/plasma biomarkers other than those for
diagnosis based on aneurysmal size for the prediction of
aneurysmal risk [3]. Proteome profiling of serum could
also facilitate the discovery of AAA and/or TAA bio-
markers for prognosis and therapeutic purposes for pa-
tients with aortic aneurysms. Circulating markers for the
progression of AAA have been investigated [4,5]. These
include extracellular matrix, matrix modulating proteases
and their inhibitors, thrombogenic proteins, cytokines and
inflammatory proteins, and lipids. Although a few of them
have clinical potential for diagnosis, further confirmative
and larger studies are needed. On the other hand, there
were no reports about circulating biomarkers for TAA so
far. It is conceivable that pathological disparities between
AAA and TAA would bear different serum/plasma bio-
markers related to each aneurysm.
The wide dynamic range of proteins and the presence of
a few major proteins such as albumin and immunoglobu-
lin complicate the analysis of serum/plasma proteomes. In
addition, serum/plasma biomarkers would be factors re-
leased in very small amounts into the blood stream, mak-
ing it difficult to detect them among other serum/plasma
proteins that exist in much larger amounts. The removal
of major proteins is a prerequisite for the identification of
serum/plasma biomarkers in small amounts. This would
increase the sample loading capacity and improve the effi-
ciency of detection of proteins that exist in small amounts.
On the other hand, most of the studies on plasma/
serum biomarker discovery have been based on compari-
son of the mean values of plasma/serum proteins from
the patient group with those from the healthy volunteer
group. However, this approach sometimes gives rise to a
large variation within each group, leading to masking of
the variation that occurs between groups. Therefore, it isexpected that the variability of serial protein profiles
within one individual is smaller than that between
groups [6]. Comparison of serial protein profiles within
one individual would facilitate identification of bio-
markers. We also expected that the postsurgical level of
a certain protein would be restored to a level similar to
that in normal control sera after resection of lesion
parts. We anticipated that monitoring changes in serum
proteomes that occur within each patient after surgical
resection of aortic aneurysm tissues would readily pro-
vide biomarkers for clinical diagnosis and treatment and
for understanding the molecular mechanisms underlying
the development of AAA and TAA.
Recently, quantitative proteome analyses using tandem
mass spectrometry (MS) with an iTRAQ labeling stra-
tegy have been developed and successfully applied to
biomarker discovery for many conditions in both tissue
[7] and serum samples [8]. In this study, serum proteins
with differential levels in postsurgery compared with
those in presurgery for the removal of aneurysmal tis-
sues in AAA and TAA patients were investigated with
iTRAQ labeling followed by nanoLC-MALDI-TOF/
TOF-MS/MS.
Results
Proteomic analyses of serum proteins with differential
levels in postsurgical sera compared with those in
presurgical sera of AAA and TAA patients
Presurgery and postsurgery serum samples were obtained
from 7 AAA and 7 TAA patients who underwent aortic
aneurysm resection. Protein levels in postsurgical sera
were compared with those in presurgical sera using
iTRAQ labeling coupled to nanoLC-MALDI-TOF/TOF-
MS/MS followed by ProteinPilot analysis. The average
iTRAQ ratios of peptides in postsurgical sera to those in
presurgical sera were calculated. A total of 180 differential
level proteins in 7 AAA patients’ sera and 199 proteins
in 7 TAA patients’ sera with 141 proteins detected in
common in both groups were identified in at least one
patient’s serum (Figure 1A). Among those proteins, 78
differential level proteins in 7 AAA patients’ sera and 86
proteins in 7 TAA patients’ sera with 75 proteins
detected in both groups were identified in at least 6
patients’ sera in each group (Figure 1B). Relative quanti-
tation by ProteinPilot analysis is based on statistical
analysis. However, since most biochemical methods tend
to have technical variation, we considered an additional
cutoff value at 1.3-fold change (≧1.3 fold or < 0.77 fold,
postsurgical vs. presurgical) for iTRAQ ratios for the
selection of serum proteins with differential levels in
postsurgical sera compared with those in presurgical sera
[9-11]. Furthermore, among them, proteins in at least two
samples in 4 volunteers’ normal control sera for which
iTRAQ ratios at the second time point (T2) to those at
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(T2 vs. T1) were excluded. We used the “unused
ProtScore” value (> 2) in ProteinPilot for an index of
protein confidence (> 99% confidence). Consequently, 63
proteins with differential levels in 7 AAA patients’ sera
and 71 proteins in 7 TAA patients’ sera with 61 proteins
detected in both groups were identified in postsurgical
sera compared with those in presurgical sera with highly
stringent criteria for protein identification (Figure 1C).
Furthermore, the proteins that show statistical significant
levels of postsurgical/presugical (patients’ sera) compared
with those of T2/T1 (control sera) (p < 0.05, patient vs.
control) were selected. Finally, 6 and 8 proteins with
significantly increased levels (≧1.3 fold, postsurgical vs.
presurgical) and 12 and 17 proteins with significantly de-
creased levels (< 0.77 fold, postsurgical vs. presurgical)
were identified in AAA and TAA patients’ sera, respect-
ively (Figure 1D).
Increased (≧1.3 fold, postsurgical vs. presurgical) and
decreased (< 0.77 fold, postsurgical vs. presurgical) serum






Figure 1 Venn diagrams showing the number of proteins with differe
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patients (Table 2) are listed in the order of iTRAQ ratios,
respectively. Among them, we investigated the correlation
between the ratios of proteins in postsurgical sera to those
in presurgical sera with gender difference of patients that
provided blood samples (Additional file 1). In increased
proteins in postsurgical sera of AAA patients (Table 1),
leucine-rich α-2-glycoprotein (LRG1) was detected [male
group (AAA patients #AAA1, #AAA2, #AAA3, #AAA4
and #AAA5) vs. female group (#AAA6 and #AAA7),
p = 0.0198 (unpaired t-test)]. In increased proteins in post-
surgical sera of TAA patients (Table 2), serum amyloid A
protein was significantly detected [male group (TAA pa-
tients #TAA1, #TAA4, #TAA5, and #TAA6) vs. female
group (#TAA2, #TAA3 and #TAA7), p = 0.0046]. In de-
creased proteins in postsurgical sera of TAA patients
(Table 2), gelsolin (male vs. female, p = 0.0357), histidine-
rich glycoprotein (male vs. female, p = 0.0132), fibronectin
(male vs. female, p = 0.0101), α-2-macroglobulin (male vs.
female, p = 0.0198), and inter-α-trypsin inhibitor heavy
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Table 1 Proteins with differential levels in postsurgical sera compared with those in presurgical sera of AAA patients
Unused protScorea % Coverageb Peptidesc (95%) Uniplot number Gene symbol Protein name iTRAQ ratiod
average ± SE






37.7 86.9 28 P02735 SAA1 Serum amyloid A protein 8.09 ± 3.60 -f Acute phase reactant
48.8 56.5 37 P01011 SERPINA3 Alpha-1-antichymotrypsin 1.88 ± 0.12 0.0006 Protease inhibitor
53.1 67.7 56 P02763 ORM1 Alpha-1-acid glycoprotein 1 1.85 ± 0.21 0.0250 Transporter
26.2 54.5 14 P02750 LRG1 Leucine-rich alpha-2-glycoprotein 1.85 ± 0.15 0.0032 Unknown
26.5 40.1 13 P02748 C9 Complement component C9 1.36 ± 0.09 0.0135 Complement
116.9 80.9 139 P01009 SERPINA1 Alpha-1-antitrypsin 1.32 ± 0.06 0.0081 Protease inhibitor
Decreased proteins
26.1 30.4 12 P06396 GSN Gelsolin 0.55 ± 0.03 0.0000 Actin scavenger
37.3 54.2 29 P02765 AHSG Alpha-2-HS-glycoprotein 0.61 ± 0.05 0.0002 Extracellular matrix
18.5 74.0 17 P02652 APOA2 Apolipoprotein A-II 0.64 ± 0.05 0.0214 Transporter
14.1 60.7 9 P02753 RBP4 Retinol-binding protein 4 0.65 ± 0.05 0.0005 Transfer/carrier protein
20.9 36.3 10 P29622 SERPINA4 Kallistatin 0.68 ± 0.06 0.0196 Protease inhibitor
10.0 25.1 6 P27169 PON1 Serum paraoxonase/arylesterase 1 0.69 ± 0.06 0.0010 Hydrolase
89.6 89.9 110 P02647 APOA1 Apolipoprotein A-I 0.70 ± 0.04 0.0238 Transporter
149.6 49.4 90 P02751 FN1 Fibronectin 0.72 ± 0.06 0.0330 Extracellular matrix
163.9 82.5 176 P02787 TF Serotransferrin 0.73 ± 0.04 0.0004 Transfer/carrier protein
36.9 50.3 20 P04196 HRG Histidine-rich glycoprotein 0.73 ± 0.03 0.0005 Adapter protein
234.7 81.7 207 P01023 A2M Alpha-2-macroglobulin 0.75 ± 0.04 0.0036 Signaling molecule
44.3 35.7 26 P19823 ITIH2 Inter-alpha-trypsin inhibitor heavy
chain H2
0.77 ± 0.06 0.0024 Protease inhibitor
aA score of protein confidence(ProtScore) for a detected protein that is calculated from the peptide confidence from spectra that are not already “used” by higher scoring proteins in the experiments.
bThe percentage of matching amino acids from identified peptides.
cThe number of distinct peptides with at least 95% confidence in the experiments.
diTRAQ ratio of postsurgical sera compared with those in presurgical sera (postsurgical vs. presurgical).
eStatistical analysis of iTRAQ ratio of postsurgery/presurgery of patients’ sera compared with that of T2/T1 of control volunteers’ sera (patient vs. control).

















Table 2 Proteins with differential levels in postsurgical sera compared with those in presurgical sera of TAA patients
Unused protScorea % Coverageb Peptidesc (95%) Uniplot number Gene symbol Protein name iTRAQ ratiod
average ± SE






46.2 82.0 48 P02735 SAA1 Serum amyloid A protein 15.65 ± 3.40 -f Acute phase protein
16.0 34.8 9 P02741 CRP C-reactive protein 4.31 ± 0.54 -f Acute phase protein
60.0 73.6 68 P02763 ORM1 Alpha-1-acid glycoprotein 1 2.61 ± 0.18 0.0002 Transporter
62.0 68.3 47 P01011 SERPINA3 Alpha-1-antichymotrypsin 2.39 ± 0.21 0.0010 Protease inhibitor
29.8 59.1 24 P02750 LRG1 Leucine-rich alpha-2-glycoprotein 2.11 ± 0.30 0.0235 Unknown
123.8 80.6 151 P01009 SERPINA1 Alpha-1-antitrypsin 1.50 ± 0.15 0.0397 Protease inhibitor
28.3 32.7 16 P02748 C9 Complement component C9 1.43 ± 0.15 0.0469 Complement
16.5 21.7 8 P09871 C1S Complement C1s subcomponent 1.30 ± 0.07 -f Complement
Decreased proteins
30.2 38.0 15 P06396 GSN Gelsolin 0.49 ± 0.05 0.0002 Actin scavenger
38.9 54.5 30 P02765 AHSG Alpha-2-HS-glycoprotein 0.51 ± 0.09 0.0008 Extracellular matrix
19.3 89.0 14 P02652 APOA2 Apolipoprotein A-II 0.52 ± 0.09 0.0258 Transporter
14.2 27.2 7 P29622 SERPINA4 Kallistatin 0.56 ± 0.08 0.0085 Protease inhibitor
95.4 92.1 97 P02647 APOA1 Apolipoprotein A-I 0.59 ± 0.09 0.0473 Transporter
16.5 53.7 10 P02753 RBP4 Retinol-binding protein 4 0.60 ± 0.10 0.0027 Transfer/carrier protein
183.4 83.7 171 P02787 TF Serotransferrin 0.60 ± 0.08 0.0021 Transfer/carrier protein
23.1 67.6 11 O95445 APOM Apolipoprotein M 0.61 ± 0.05 0.0050 Transporter
36.3 46.3 19 P04196 HRG Histidine-rich glycoprotein 0.61 ± 0.07 0.0061 Adapter protein
156.2 49.9 98 P02751 FN1 Fibronectin 0.65 ± 0.07 0.0261 Extracellular matrix
13.3 27.3 7 P27169 PON1 Serum paraoxonase/arylesterase 1 0.66 ± 0.07 0.0011 Hydrolase
16.4 22.3 7 P03952 KLKB1 Plasma kallikrein 0.66 ± 0.09 0.0191 Protease
12.0 78.2 7 P02655 APOC2 Apolipoprotein C-II 0.66 ± 0.14 0.0387 Transporter
289.1 78.8 228 P01023 A2M Alpha-2-macroglobulin 0.66 ± 0.05 0.0027 Signaling molecule
59.1 41.9 34 P19823 ITIH2 Inter-alpha-trypsin inhibitor heavy
chain H2
0.68 ± 0.08 0.0043 Protease inhibitor
28.4 38.4 14 P43652 AFM Afamin 0.70 ± 0.08 0.0041 Transfer/carrier protein
30.5 44.7 18 P05546 SERPIND1 Heparin cofactor 2 0.76 ± 0.09 0.0424 Protease inhibitor
aA score of protein confidence(ProtScore) for a detected protein that is calculated from the peptide confidence from spectra that are not already “used” by higher scoring proteins in the experiments.
bThe percentage of matching amino acids from identified peptides.
cThe number of distinct peptides with at least 95% confidence in the experiments.
diTRAQ ratio of postsurgical sera compared with those in presurgical sera (postsurgical vs. presurgical).
eStatistical analysis of iTRAQ ratio of postsurgery/presurgery of patients’ sera compared with that of T2/T1 of control volunteers’ sera (patient vs. control).
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http://www.proteomesci.com/content/11/1/27detected. Furthermore we also examined the correlation
between the ratios of proteins in postsurgical sera to those
in presurgical sera with the number of days of blood sam-
pling before and after surgery (Additional file 1). In in-
creased proteins in postsurgical sera of AAA patients
(Table 1), serum amyloid A protein was significantly
detected [grouping based on the number of days before
surgery, less than 1 week group (#AAA1, #AAA3 and
#AAA6) vs. more than 1 week group (#AAA2, #AAA4,
#AAA5 and #AAA7), p = 0.0374].
As mentioned below, among them two proteins
(gelsolin and kallistatin) in patients’ sera with AAA and
three proteins (gelsolin, kallistatin and afamin) in pa-
tients’ sera with TAA were finally examined by Western
blot analyses with other presurgery and postsurgery
blood samples. Furthermore, a positive acute-phase pro-
tein, α-2-macroglobulin was also confirmed by Western
blot analysis.
Verification of iTRAQ ratio by Western blot analysis
To confirm the accuracy of the quantitative results of
iTRAQ ratios, some proteins were quantified again by
Western blot analysis. The relative amounts of LRG1CBB
49kDa
























































Figure 2 Confirmation of iTRAQ ratio by Western blot analyses. Weste
LRG1) (A) and anti-fibronectin (FN) (B) antibodies in presurgical (pre) and p
performed. Representative photos are shown. To confirm equal levels of pr
Blue (CBB) are shown in the lowest panel. The intensity of each band that
measured. Ratios of levels of LRG1 (C) and fibronectin (F) in postsurgical se
determined by band intensity. Ratios of levels of LRG1 (D) and fibronectin
#TAA4 were also determined by band intensity. Furthermore, Western blot
points (T1 and T2) in serum of a control volunteer #C3 were performed. Ra
those at T1 (1.0) in serum of the control volunteer were determined by ban
and statistical analysis was performed using the paired t-test. ** p < 0.01. *p(iTRAQ ratio = 1.99, postsurgical vs. presurgical) and fibro-
nectin (iTRAQ ratio = 0.69, postsurgical vs. presurgical)
for AAA patient #AAA2 (Figures 2A,B,C,F) and LRG1
(iTRAQ ratio = 2.24, postsurgical vs. presurgical) and fibro-
nectin (iTRAQ ratio = 0.63, postsurgical vs. presurgical) for
TAA patient #TAA4 (Figures 2A,B,D,G) in postsurgical
sera compared with those in presurgical sera were exam-
ined by Western blot analysis. The ratios of levels of LRG1
and fibronectin in postsurgical sera compared with those
in presurgical sera (1.0) in the AAA and TAA patients were
determined by band intensity, and they were 1.62-fold
(Figure 2C) and 0.69-fold (Figure 2F), respectively, in sera
of AAA patients and 1.37-fold (Figure 2D) and 0.63-fold
(Figure 2G), respectively, in sera of TAA patients. Almost
the same results were obtained in AAA patient #AAA3
and TAA patient #TAA1 (data not shown). Similarly,
iTRAQ ratios of LRG1 (0.93) and fibronectin (0.96) in
serum of a control volunteer #C3 collected at two different
time points (T1 and T2) were almost identical to the
ratios determined by Western blot analysis (LRG1, 1.01;
fibronectin, 0.97) (Figures 2A,B,E,H). These results indi-
cated that iTRAQ ratios are almost consistent with quanti-
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rn blot analyses with anti-leucine-rich α-2-glycoprotein (referred to as
ostsurgical (post) sera of patient #AAA2 and patient #TAA4 were
oteins per lane, non-specific proteins stained with Coomassie Brilliant
reacted with the corresponding antibody indicated by an arrow was
ra compared with those in presurgical sera (1.0) in #AAA2 were
(G) in postsurgical sera compared with those in presurgical sera (1.0) in
analyses with anti-LRG1 (A) and anti-FN (B) at two different time
tios of levels of LRG1 (E) and fibronectin (H) at T2 compared with
d intensity. Means ± SE of quadruplicate experiments were calculated,
< 0.05.
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and kallistatin in presurgical and postsurgical sera by
Western blot analysis
All of the proteins on the list of serum proteins that
were increased (≧ 1.3 fold, postsurgical vs. presurgical)
in postsurgical sera compared with those in presurgical
sera of AAA patients and TAA patients (Tables 1 and 2)
were inflammatory response markers with increased
levels during acute-phase response (see Discussion)
[12-16]. These proteins include serum amyloid A pro-
tein, α-1-antichymotrypsin, α-1-acid glycoprotein 1,
LRG1, complement component C9, and α-1-antitrypsin
in both AAA and TAA patients (Tables 1 and 2). C-
reactive protein and complement C1s subcomponent
were also increased in postsurgical sera of TAA patients
(Table 2).
Intriguingly, five negative acute-phase proteins (retinol-
binding protein 4 [17], fibronectin [18], serotransferrin
[19], histidine-rich glycoprotein [20] and inter-α-trypsin
inhibitor heavy chain H2 [21]) were decreased in postsur-
gical sera compared with those in presurgical sera of both
AAA and TAA patients. Some constituents of high-122kDa
pre  post   N  
















Figure 3 Examination of the decreased level of α-2-macroglobulin in
AAA and TAA patients, and restoration of its level to that in normal c
antibody in presurgical (pre) and postsurgical (post) sera of 12 patients wit
by arrows. Representative photos of two each of patients (patient no. #AAA
control sera (N) are shown. To confirm equal levels of proteins per lane, no
(CBB). The intensity of each band in presurgical and postsurgical sera of 12
with anti-α-2-macroglobulin antibody was measured. Ratios of levels of α-2
sera compared with that in the mixture of 10 normal control sera (1.0) wer
were calculated, and statistical analysis was performed using the paired t-te
using the unpaired t-test between postsurgical and normal control data. **density lipoprotein (HDL) that are suppressed during the
acute-phase response [22], apolipoprotein (apo) A-I, apo
A-II, and serum paraoxonase/arylesterase 1 in the case of
sera from AAA patients and apo A-I, apo A-II, apo C-II,
apo M, and serum paraoxonase/arylesterase 1 in the case
of sera from TAA patients, were also included in the de-
creased proteins.
On the other hand, a positive acute-phase protein, α-
2-macroglobulin, was unexpectedly decreased in post-
surgical sera compared with that in presurgical sera of
both AAA and TAA patients (Tables 1 and 2). There-
fore, by Western blot analysis, we investigated the de-
creased levels of α-2-macroglobulin, using postsurgical
sera compared with presurgical sera from 12 other AAA
patients and 10 other TAA patients, and examined
whether the level of α-2-macroglobulin in postsurgical
sera is similar to that in normal control sera. If the level
of α-2-macroglobulin in postsurgical sera returns to a
level similar to that in control sera, α-2-macroglobulin
would be a candidate of disease biomarkers for AAA
and TAA. Consequently, we confirmed the decrease in
α-2-macroglobulin in postsurgical sera (Figure 3). In122kDa















postsurgical sera compared with that in presurgical sera of both
ontrol sera. Western blsot analyses with anti-α-2-macroglobulin
h AAA (A) and 10 patients with TAA (B) were performed as indicated
11, #AAA13, #TAA10 and #TAA11) as well as a mixture of 10 normal
n-specific proteins stained with Coomassie Brilliant Blue are shown
AAA and 10 TAA patients and 10 normal control sera that reacted
-macroglobulin in presurgical and postsurgical sera and normal control
e determined by band intensity. Means ± SE of triplicate experiments
st between presurgical and postsurgical data, whereas it was done
p < 0.01.
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sera of TAA patients (Figure 3B) but not in postsurgical
sera of AAA patients (Figure 3A) was similar to that in
normal control sera, indicating that α-2-macroglobulin
would be a candidate of disease biomarkers for TAA.
Among other decreased serum proteins in postsurgical
sera compared with those in presurgical sera, we were
interested in proteins such as gelsolin and kallistatin in
AAA patients and gelsolin, kallistatin and afamin in
TAA patients, for which detailed analyses in connection
with aortic aneurysms have not been performed. There-
fore, we further investigated these decreased levels of
proteins by Western blot analysis (Figure 4). As a result,
we confirmed decreased levels of proteins such as gelsolin
and kallistatin in postsurgical sera of AAA patients
(Figures 4A,B) and gelsolin, kallistatin, and afamin in post-
surgical sera of TAA patients (Figures 4C-E) compared
with those in presurgical sera by Western blot analysis.
Subsequently, we investigated whether the protein levels
in postsurgical sera are similar to those in normal control
sera. In consequence, only the levels of kallistatin in post-
surgical sera of both AAA and TAA patients were similar
to those in normal control sera (Figures 4B,D). The level
of gelsolin in the postsurgical sera of AAA patients
(Figure 4A) and the levels of gelsolin and afamin in post-
surgical sera of TAA patients (Figures 4C,E) were not
similar to those in normal control sera. Thus, in postsurgi-
cal sera compared to presurgical sera only kallistatin
showed a decreased level similar to that in normal control
sera, indicating that kallistatin would also be a candidate
of disease biomarkers for AAA and TAA.
Discussion
Serum proteins often possess information on diseases
concerning the overall pathologic status of patients.
Thus, circulating serum biomarkers could play an im-
portant role in the diagnosis of diseases and might also
have a role in predicting progression of diseases. To
identify critical molecular mechanisms underlying AAA
formation, circulating serum biomarkers in patients and
controls have been assessed in some case–control stu-
dies [4,5]. So far, most proteomic analyses attempting to
reveal biological markers for AAA have been performed
in AAA tissue samples [23]. Only one proteomic study
for the identification of plasma biomarkers for AAA,
which led to the identification of five differentially up-
regulated proteins in plasma samples of AAA patients
compared to control patients, has been published [24].
However, the broad range of molecular alterations that
occur in postsurgical sera compared to presurgical sera
of one patient with AAA or TAA has not been eluci-
dated. We speculated that a comparison of presurgical
and postsurgical protein profiles within one patient would
facilitate discovery of disease biomarkers. We expectedthat if the postsurgical level of a certain protein that shows
a differential level between presurgical and postsurgical
sera is restored to a level similar to that in normal control
sera after the resection of AAA or TAA, the protein would
be a disease biomarker. In this study, using an approach
with iTRAQ labeling followed by nanoLC-MALDI-TOF/
TOF-MS/MS analysis, we determined proteomic profiles
of proteins with differential levels in postsurgical sera
compared with those in presurgical sera of AAA and TAA
patients who underwent aortic aneurysm resections. Con-
sequently, 6 and 8 proteins with increased level (≧1.3 fold,
postsurgical vs. presurgical) and 12 and 17 proteins with
decreased level (< 0.77 fold, postsurgical vs. presurgical)
were identified in postsurgical sera compared with those
in presurgical sera of AAA and TAA patients, respectively.
All of the proteins with increased levels (≧1.3 fold, post-
surgical vs. presurgical) in postsurgical sera compared
with those in presurgical sera of both AAA and TAA pa-
tients were positive acute-phase proteins such as serum
amyloid A protein and α-1-acid glycoprotein 1. On the
other hand, five serum proteins including retinol-binding
protein 4, serotransferrin and others, and apolipoproteins
such as apo A-I in HDL known as negative acute-phase
proteins were decreased in postsurgical sera compared
with those in presurgical sera of both AAA and TAA pa-
tients. Since postsurgical blood sampling was performed 4
to 20 days (Additional file 1) after surgical injury for aortic
aneurysm resections, the increased levels of positive
acute-phase proteins and the decreased levels of negative
acute-phase proteins in postsurgical sera compared with
those in presurgical sera might have been caused by the
inflammatory response which is part of the normal re-
sponse to surgical injury and not by specific resection of
the diseased aortic aneurysmal tissues.
On the other hand, among other decreased proteins in
postsurgical sera compared with those in presurgical sera,
whichwe focused on and confirmed the decrease byWestern
blot analyses, we found that the decreased levels of kallistatin
in both AAA and TAA patients’ postsurgical sera and α-2
-macroglobulin in TAA patients’ postsurgical sera are re-
stored to levels similar to those in normal control sera. These
results indicate that kallistatin and α-2-macroglobulin would
be candidates of disease biomarkers for both AAA and TAA
patients and TAA patients, respectively.
Kallistatin was initially discovered as a tissue kallikrein
inhibitor and was shown to have multifaceted effects
such as anti-inflammation, anti-oxidative stress, and anti-
angiogensis effects [25]. Administration of kallistatin pre-
vented cardiac injury such as fibrosis and hypertrophy by
inhibiting oxidative stress [26]. Since inflammation and
oxidative-stress considerably arise in aortic aneurysmal
tissues, the increase in kallistatin in patients’ sera would

























pre  post   N  pre   post   N
pre  post   N
CBB
CBB




pre   post    N  pre   post    N






















pre   post   N
*
pre  post   N  
**
pre  post   N pre  post   N
#AAA15 #AAA16 #AAA9 #AAA10












Figure 4 Examination of the decreased levels of some proteins in postsurgical sera compared with those in presurgical sera of both
AAA and TAA patients, and restoration of their levels to those in normal control sera. Western blot analyses with anti-gelsolin (A,C), and
anti-kallistatin (B,D), and anti-afamin (E) antibodies in presurgical (pre) and postsurgical (post) sera in 12 patients with AAA (A,B) and 10 patients
with TAA (C-E) were performed as indicated by arrows. Representative photos of two each of patients concerning to each protein (patient no.
#AAA15, #AAA16, #TAA9 and #TAA12 for gelsolin; #AAA9, #AAA10, #TAA15 and #TAA16 for kallistatin; #TAA11 and #TAA15 for afamin) as well as
mixture of 10 normal control sera (N) are shown. To confirm equal levels of proteins per lane, non-specific proteins stained with Coomassie
Brilliant Blue are shown (CBB). The intensity of each band in presurgical and postsurgical sera of 12 AAA and 10 TAA patients and 10 normal
control sera that reacted with each antibody was measured. Ratios of levels of each protein in presurgical and postsurgical sera and normal
control sera compared with that in the mixture of 10 normal control sera (1.0) were determined by band intensity. Means ± SE of triplicate
experiments were calculated, and statistical analysis was performed using paired t-test between presurgical and postsurgical data, whereas it was
done using unpaired t-test between presurgical or postsurgical and normal control data. ** p < 0.01. * p < 0.05.
Satoh et al. Proteome Science 2013, 11:27 Page 9 of 13
http://www.proteomesci.com/content/11/1/27The primary function of α-2-macroglobulin, one of the
positive acute-phase proteins, is inhibition of a broad
spectrum of proteases during tissue injury at sites of
inflammation [27]. It has been reported that α-2-macro-
globulin is a valuable serum marker for the diagnosis of
cardiac diseases [28]. Aortic aneurysms are characterizedby inflammation with infiltration of inflammatory cells,
induction of inflammatory cytokines, and release of
reactive oxygen species. However, the differences in the
physical structures of abdominal and thoracic aortas
might result in differences in the inflammatory re-
sponses of AAA and TAA [2]. It is known that a Th2-
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in AAA, whereas a Th1-predominant immune response
occurs in TAA. These differences in inflammatory re-
sponses in AAA and TAA may contribute to the fact
that α-2-macroglobulin would be a candidate of disease
biomarkers only in TAA patients.
Acosta-Martin et al. [24] identified 19 plasma diag-
nostic biomarker proteins potentially involved in AAA
biological mechanisms using quantitative MS analysis.
Among them, five proteins such as kallistatin, protein
AMBP, gelsolin, heparin cofactor 2, α-2-antiplasmin
were found in common in the 63 proteins disclosed in
AAA patients’ sera in the present study. Moreover, they
verified the increased levels of kallistatin and protein
AMBP in individual plasma of AAA patients by
Western blot analysis. In agreement with this, in the
present study the level of kallistatin in presurgical sera
was higher than in postsurgical sera and control sera as
shown in Table 1 and Figure 4B. Furthermore, in the
present study the level of protein AMBP in presurgical
sera was moderately higher than that in postsurgical
sera (iTRAQ ratio =1.17, presurgical vs. postsurgical).
These evidences more strengthen the idea that kallistatin
is a candidate of disease biomarkers for AAA.
So far some extracellular matrices such as amino-
terminal propeptide of type III procollagen (PIIINP) and
carboxyterminal propeptide of type I procollagen (PICP),
thrombus-associated proteins such as fibrinogen, D-dimer
and tissue plasminogen activator (tPA) and matrix-
degrading enzymes such as matrix metalloproteinase-9
(MMP-9) have been reported as potential circulating
biomarkers for AAA diagnosis in case–control study
[4]. Interestingly, SanGiorgi et al. [29] showed that
MMP-3 and MMP-9 are effective monitors from 1 to
6 months after AAA surgery. However, these known
circulating biomarkers associated with AAA could not
be identified in the present study. The levels of these
circulating biomarkers in AAA patients might remain
high for a while after the surgery, and they might not
change in the investigated periods (4 to 12 days) after
the surgery compared with those in presurgery.
Conclusions
Proteomic analyses of postsurgical sera compared with
presurgical sera of patients with AAA and TAA were per-
formed by using iTRAQ labeling followed by nanoLC-
MALDI-TOF/TOF-MS/MS analysis. Among identified
proteins with differential levels between postsurgical sera
and presurgical sera, kallistatin in both AAA and TAA
patients’ sera and α-2-macroglobulin in TAA patients’ sera
might be candidates of serum biomarkers for aortic
aneurysms. Our results provide valuable information on
the underlining mechanisms of AAA and TAA and will




Blood samples were collected after approval from the Eth-
ics Committee of Shimane University School of Medicine,
Japan. The participants gave informed consent. Blood
samples for quantitative proteome analyses were collected
at presurgery and postsurgery from 7 AAA patients
(5 males, 2 females; average age, 73.9 years) and 7 TAA
patients (4 males, 3 females; average age, 73.1 years) who
underwent aortic aneurysm resection during approxi-
mately 2 years in Shimane University Hospital. Presurgical
and postsurgical blood samples were taken at an average
of 7.1 days before and an average of 9.3 days after surgery,
respectively. Atherosclerosis with calcification was macro-
scopically visible in most of the aneurysmal specimens
from each patient. As normal control samples for quanti-
tative proteome analyses, blood samples were collected
from 4 healthy volunteers (2 males, 2 females; average age,
42.0 years) at two time points [first time point (T1) and
second time point (T2)] with a 14-day interval. Age,
gender, and time of sample collection of patients and con-
trol volunteers were shown in Additional file 1. Other
presurgery and postsurgery blood samples were collected
from patients with AAA (8 males, 4 females; average age,
79.4 years) and TAA (7 males, 3 females; average age,
67.6 years) who underwent aortic aneurysm resection dur-
ing approximately 2 years in Shimane University Hospital
for confirmation by Western blot analysis. Mixture of sera
collected from 10 healthy volunteers (7 males, 3 females;
average age, 42.0 years) was used as normal control sam-
ples for Western blot analysis. Age, gender, and time of
sample collection of other patients and other control
volunteers were shown in Additional file 2. Age matching
of patients and volunteers was not fulfilled in the present
study. Blood samples were centrifuged and the plasma
layer was removed. Serum samples were stored at −80°C
until use.
Immunodepletion of abundant serum proteins
To remove the two most-abundant serum proteins [albu-
min and immunoglobulin (Ig)G], an immunodepletion
column (Albumin & IgG depletion SpinTrap) from GE
Healthcare (Buckinghamshire, UK) was used according to
the manufacturer’s instructions. Briefly, the column was
equilibrated with binding buffer (20 mM sodium phos-
phate, 0.15 M sodium chloride). After centrifugation,
50 μl of serum was diluted with an equivalent volume of
binding buffer and then applied to the column and incu-
bated for 5 min. After centrifugation for 30 s at 800 g, the
eluate was collected. A further 100 μl of binding buffer
was applied to the column and centrifuged. This elution
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and then desalted, and its buffer was exchanged with
50 mM triethylammonium bicarbonate (TEAB) (Sigma,
Tokyo, Japan) using spin concentrators (Corning,
Tokyo, Japan). The protein concentration was deter-
mined using a bicinchoninic acid (BCA) Protein Assay
Reagent (Thermo Fisher Scientific, Rockford, IL, USA).
Denaturation, reduction, trypsin digestion, iTRAQ
labeling, and strong cation exchange (SCX)
chromatography
Sample preparation was performed accordingly to theman-
ual supplied by AB Sciex (Foster, CA, USA) and our previ-
ous paper [30]. Briefly, equal amounts of immunodepleted
presurgical and postsurgical serum samples were denatured
by sodium dodecyl sulfate (SDS) and reduced by [tris-
(2-carboxyethyl)phosphine (TCEP)]. Then cysteine alkyl-
ation was performed with methylmethanethiosulfonate
(MMTS). Thereafter, each sample was digested by trypsin
(AB Sciex). Each digest was labeled with a different iTRAQ
tag by an iTRAQ Reagent Multiplex kit (AB Sciex). iTRAQ
label 114 or 115 was used for labeling presurgical serum
samples, and iTRAQ label 116 or 117 was used for postsur-
gical serum samples. Then the labeled presurgical and
postsurgical samples were combined. This experiment was
conducted for each patient. For the control samples col-
lected at two time points, the former sample was labeled
with iTRAQ label 114 or 115 and the latter sample was
labeled with iTRAQ label 116 or 117. Then the labeled sam-
ples were combined. This experiment was conducted for
each volunteer. After that, the combined samples were frac-
tionated into six fractions by strong cation exchange (SCX)
chromatography according to the instructions of the manu-
facturer (AB Sciex). Then each fraction was desalted by a
Sep-Pac C18 cartridge according to the instructions of the
manufacturer (Waters, Milford, MA, USA).
NanoLC and MALDI-TOF/TOF MS/MS analysis
One fraction from SCX chromatography was fractionated
to 171 spots with a DiNa nanoLC system (KYA Tech,
Tokyo, Japan) and collected onto an Opti-TOF LC/MALDI
384 target plate (AB Sciex) using a Dina MaP fraction col-
lector (KYA Tech) according to the instructions of the
manufacturer (KYA Tech) and our previous paper [31].
Offline spotted peptide samples were analyzed on a 5800
MALDI-TOF/TOF MS/MS Analyzer with TOF/TOF
Series software (version 4.0) (AB Sciex). MS spectra were
acquired betweenm/z 800 and 4000with positive ionmode.
Parent ions of des-Arg1-bradykinin, angiotensin I, Glu1-
fibrinopeptide B, adrenocorticotrophic hormone (ACTH)
(clip 1–17), ACTH (clip 18–39) and ACTH (clip 7–38), di-
luted in a matrix [4 mg/ml α-cyano-4-hydroxycinnamic
acid (CHCA), Wako, Osaka, Japan], were used for calibra-
tion. Monoisotopic precursor selection for MS/MS wascarried out by automatic precursor selection with an in-
terpretation method using the DynamicExit Algorithm
(AB Sciex). MS/MS data obtained by the 5800 MALDI-
TOF/TOF were analyzed by ProteinPilot™ software (ver-
sion 3.0) with the Paragon protein database search
algorithm (AB Sciex) [32]. Statistic method of iTRAQ
analysis was according to ProteinPilot™ software (ver-
sion 3.0). Each MS/MS spectrum was searched against
the database constructed by AB Sciex (version 20081216,
20,489 entries). Based on the iTRAQ ratio of postsurgery
to presurgery of each peptide, quatitative changes of each
protein in presurgical and postsurgical sera were cal-
culated. The comparison between the iTRAQ ratio of
postsurgery to presurgery of patients and that of T2 to T1
of control volunteers was statistically performed by the
unpaired t-test (two side test), with p < 0.05 being consid-
ered statistically significant.
Bioinformatic analysis
Panther software (version 7.2) (http://www.pantherdb.
org/) was used for protein classification analysis. The
annotations of identified proteins were acquired from
the Uniprot database (http://www.uniprot.org/) and ap-
propriate literature.
Western blot analysis
Crude sera for the analyses of α-2-macroglobulin, kallistatin,
gelsolin and afamin or albumin- and IgG-depleted sera for
the analyses of fibronectin and leucine-rich α-2-glycoprotein
(LRG1) were electrophoresed through sodium dodecyl
sulfate-polyacrylamide gel (SDS-PAGE), and then the
proteins were transferred onto Hybond ECL nitrocellulose
membranes (GE Healthcare Japan, Hino, Japan). The
amount of crude sera (μl) and albumin- and IgG-depleted
sera (μg) used for each analysis was as follows: α-2-macro-
globulin (0.5 μl), kallistatin (2 μl), gelsolin (0.5 μl), afamin
(2 μl), fibronectin (2.5 μg) and LRG1 (3.3 μg). Western
blot analyses were performed as described in our previous
paper [33]. The membranes were reacted with rabbit
polyclonal anti-fibronectin antibody (Sigma-Aldrich, St.
Louis, MO, USA), mouse monoclonal anti-LRG1 antibody
(Abnova,Taipei,Taiwan), rabbit polyclonal anti-α-2-macro-
globulin antibody (Abcam, Tokyo, Japan), goat polyclonal
anti-kallistatin antibody (R &D Systems, Minneapolis, MN,
USA), mouse monoclonal anti-gelsolin antibody (Sigma-
Aldrich, St. Louis, MO, USA) or goat polyclonal anti-
afamin antibody (GeneTex, Irvine, CA, USA). Then the
proteins on the nitrocellulose membranes were reacted
with anti-rabbit, anti-mouse or anti-goat Alex Flour
680-conjugated or IRDye 800-conjugated IgG (LI-COR,
Lincoln, NE, USA), followed by visualization using the in-
frared imaging system Odyssey (LI-COR). The intensity of
each band reacted with a corresponding antibody was mea-
sured for densitometric analyses of each protein level. Data
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tical significance by the t-test (two side test). Its significance
was set with p < 0.05. Results are expressed as means ±
standard error (SE).
Additional files
Additional file 1: Sera used for iTRAQ labeling followed by nanoLC-
MALDI-TOF/TOF-MS/MS analysis.
Additional file 2: Sera of other patients used for Western blot
analysis.
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